Why the study?
Little is understood regarding the mechanism of action of myocardial-derived decellularized extracellular matrix hydrogel in chronic myocardial infarction.
Does injectable myocardial matrix hydrogel mitigate negative left ventricular remodeling in a small animal chronic MI model?
Does injectable myocardial matrix hydrogel mitigate negative left ventricular remodeling in a small animal chronic MI model?
Myocardial matrix hydrogel mitigates negative LV remodeling and modulates HF progression pathways in a chronic MI small animal model, providing mechanistic insight into its potential efficacy.
Hypothesis-generating for myocardial ECM hydrogel in chronic MI; larger trials needed before ischemic HF adoption.
Summary A first-in-man clinical study on a myocardial-derived decellularized extracellular matrix (ECM) hydrogel yielded evidence for potential efficacy in ischemic heart failure (HF) patients. However, little is understood about the mechanism of action in chronic myocardial infarction (MI). In this study we investigated efficacy and mechanism by which the myocardial matrix hydrogel can mitigate negative left ventricular (LV) remodeling in a chronic model of MI. Assessment of cardiac function via magnetic resonance imaging (MRI) demonstrated preservation of LV volumes and apical wall thickening. Differential gene expression analyses showed the matrix is able to prevent worsening HF in a small animal chronic MI model through modulation of the immune response, downregulation of pathways involved in HF progression and fibrosis, and upregulation of genes important for cardiac muscle contraction.
No takes yet. Share an insight, caveat, or question.
Diaz et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: